Please ensure Javascript is enabled for purposes of website accessibility

Why Fortress Biotech Stock Is Sinking Today

By Prosper Junior Bakiny - Apr 13, 2021 at 3:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were not thrilled with the company's latest regulatory update.

What happened?

Shares of biopharmaceutical company Fortress Biotech (FBIO -4.14%) are dropping sharply on Tuesday after the company announced a regulatory update regarding one of its subsidiaries, Avenue Therapeutics (ATXI 1.36%). As of 2:49 p.m. EDT, shares of Fortress Biotech were down by 11.3%.

So what

Avenue Therapeutics' New Drug Application (NDA) for IV tramadol, a medication intended for the management of acute pain in patients who require an opioid, has been in limbo for several months. In October, the U.S. Food and Drug Administration (FDA) issued a Complete Letter Response (CLR) to Avenue Therapeutics for this medicine. 

After a productive meeting with the regulatory agency, Avenue Therapeutics planned on resubmitting an NDA for IV tramadol in February. The company did so, and it received an acknowledgment letter from the FDA stating that its NDA resubmission for IV tramadol was a complete, class 1 response to the agency's CLR. 

Five downward-pointing arrows on a blackboard.

Image source: Getty Images.

The FDA classifying Avenue Therapeutics' response to its CLR as a class 1 response was good news as these typically come with shorter review times (two months instead of six months for class 2 responses). However, Avenue Therapeutics announced today that the FDA is still reviewing its NDA for IV tramadol and has yet to reach a decision regarding the medicine. This is despite the fact that the agency had assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 12 after the healthcare company resubmitted its NDA for IV tramadol.

Now what

It isn't clear whether this delayed response from the FDA will eventually result in another rejection for IV tramadol. However, the market does not like uncertainty, and this development adds a whole lot of uncertainty to the mix for Avenue Therapeutics. As its parent company, Fortress Biotech is also feeling the effects of this news. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fortress Biotech, Inc. Stock Quote
Fortress Biotech, Inc.
FBIO
$0.82 (-4.14%) $0.04
Avenue Therapeutics, Inc. Stock Quote
Avenue Therapeutics, Inc.
ATXI
$0.24 (1.36%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.